GlassScriptPhysician profile
Pamela L Alvarez
NPI 1881627743
$19,474.04
in general payments reported to CMS, 2019-2025
62 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,428 · 2020: $1,939 · 2021: $3,162 · 2022: $3,533 · 2023: $3,039 · 2024: $3,000 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,195 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,195.18 |
| Education | $216.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,143.09 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $3,070.21 | 2021-2025 | Qulipta, Ubrelvy, Duopa |
| Ucb, INC. | $1,473.96 | 2019-2025 | Briviact, Zilbrysq, Nayzilam |
| Amgen INC. | $1,293.20 | 2019-2024 | Aimovig |
| Lilly USA, LLC | $663.46 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Acadia Pharmaceuticals INC | $659.16 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $642.43 | 2022-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $641.35 | 2019-2025 | Ultomiris |
| Eisai INC. | $496.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $470.26 | 2019-2021 | |
| Biogen, INC. | $450.28 | 2019-2025 | Leqembi |
| Sk Life Science, INC. | $408.36 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $382.56 | 2019-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $330.07 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $327.00 | 2023-2025 | Rexulti, Nuedexta |
Show all 59 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.